| Cat. No. |
Product Name |
Information |
| PC-Ab1077 |
Anti-mouse PD-1 mAb, RMP1-14
|
Anti-Mouse PD-1 (RMP1-14 Biosimilar) is a recombinant mouse mAb against murine PD-1 for in vivo use. In ABC-DLBCL model showed that combined venetoclax and RMP1-14 significantly increased the overall survival of lymphoma bearing animals.. |
| PC-Ab1076 |
Anti-mouse CTLA4 mAb
|
. |
| PC-Ab1075 |
Mavrilimumab
|
Mavrilimumab (KPL-301, CAM3001) is a monoclonal antibody to GM-CSF receptor-α chain, and competitive antagonist of GM-CSF signaling. Mavrilimumab also is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19. Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVI |
| PC-Ab1074 |
MDX-1342
|
MDX-1342 is a fully human monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) effector function, targeting CD19-membrane receptor which is highly expressed on malignant chronic lymphocytic leukemia (CLL) cells. MDX-1342 blocks activation of B cell stimulation, decreasing the number of cancerous B cell clones.. |
| PC-Ab1073 |
Anti-human SIGLEC15 mAb, 5G-12
|
Anti-Human SIGLEC15 (5G-12) is a high affinity humanized IgG4 mAb specific for SIGLEC15 (S15, Sialic Acid-Binding Ig-Like Lectin 15), blocks Siglec-15-mediated suppression of murine OT-I responses to 293T-K b OVA-S15 + or OVA 257-264-pulsed mouse primary macrophages, inhibits the growth of established tumors in murine models.. |
| PC-Ab1072 |
Vedolizumab
|
Vedolizumab (MLN-0002) is a humanized monoclonal antibody, which acts against α 4 β 7 integrin heterodimer and blocks the interaction of α4β7 integrin with mucosal address in cell adhesion molecule-1 (MAdCAM-1). Vedolizumab inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) parenchymal tissue, impairs the migration of gut-homing lymphocytes into the mucosa, thereby acting as a gut-selective anti-lymphocyte-trafficking immunomodulator.. |
| PC-Ab1071 |
Adalimumab
|
Adalimumab (D2E7, ABT-D2E7) is a recombinant human IgG1 monoclonal antibody specific for human TNF-α, specifically targets and blocks TNF-alpha which contributes to the inflammation that causes the abscesses, inflammatory nodules, and draining fistulas in hidradenitis suppurativa (HS).. |
| PC-Ab1070 |
Erenumab
|
Erenumab (AMG-334) is a fully human monoclonal antibody that selectively and potently binds to the canonical CGRP (calcitonin gene-related peptide receptor). Erenumab (AMG-334) competes with [(125)I]-CGRP binding to the human CGRP receptor, with a Ki of 0.02 nM. AMG 334 fully inhibited CGRP-stimulated cAMP production with an IC50 of 2.3 nM in cell-based functional assays (human CGRP receptor) and was 5000-fold more selective for the CGRP receptor than other human calcitonin family receptors, inc |
| PC-Ab1069 |
MK-4166
|
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 decreased induction and suppressive effects of T regs in vitro In human TIL cultures, MK-4166 induced phosphorylation of NFκB and increased expression of dual specificity phosphatase 6 (DUSP6), indicating that MK-4166 activated downstream NFκB and Erk signaling pathways.. |
| PC-Ab1068 |
Caplacizumab
|
Caplacizumab (ALX0081) is a humanized single variable domain immunoglobulin (nanobody) against the von Willebrand factor (VWF). by targetting the A1 domain of the ultra-large von Willebrand factor which in order inhibits the interaction with the glycoprotein Ib-IX-V receptor in the platelets. Caplacizumab has used to treat acquired thrombotic thrombocytopenic purpura (aTTP).. |
| PC-Ab1067 |
Tislelizumab
|
Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. Tislelizumab (BGB-A317) binds to and blocks human PD-1 with high affinity and specificity, shows anti-tumor activity through activation of antibody-dependent macrophage-mediated killing of T effector cells.. |
| PC-Ab1066 |
Omburtamab
|
8H9 is an IgG1 mAb that targets B7-H3, it is broadly reactive with human solid tumors, including embryonal tumors and carcinomas. 131I-omburtamab, a monoclonal antibody called 8H9 linked to a radioactive agent called iodine 131. 8H9 attaches to B7H3 positive tumor cells in a targeted way and delivers iodine 131 to kill them. 8H9 has been successfully used for radioimmunotherapy for patients with B7-H3(+) tumors. In early phase human clinical trials, 131I-8H9 prolongs survival among high risk pat |
